Shares of United Therapeutics Corp. (UTHR) - Get Free Report jumped 8.6% to $137.82 in morning trading on Friday, Aug. 4, on the heels of an Evening Standard report that GlaxoSmithKline plc (GSK) - Get Free Report could be among the suitors for United Therapeutics.
The report stated that Gilead Sciences Inc. (GILD) - Get Free Report "is thought to be the frontrunner for United in what could become an auction process," adding that other potential suitors include Novartis AG NVS.
United Therapeutics on July 27 reported second-quarter non-GAAP earnings per diluted share of $4.37, down 1% from the same period a year ago. Revenue rose 8% to $444.6 million, which marks the company's highest quarterly net revenue level ever, chairman and CEO Martine Rothblatt noted in the news release.
Analysts had projected adjusted EPS of $3.79 on revenue of $391.50 million, according to Bloomberg.
Meanwhile, Epizyme, Inc. (EPZM) - Get Free Report on Friday reported a loss per share of 48 cents, compared with a loss of 49 cents in the year-ago period. The company said $10 million of revenue was recognized in the second quarter of 2017, compared to $0.5 million in the same period last year.
Shares of Epizyme were up 1.2% to $12.60.
In other news, Eli Lilly & Co. (LLY) - Get Free Report said Friday that lasmiditan, a potential treatment for migraine, achieved its primary endpoint in Spartan, a second Phase 3 study. Shares of Lilly were trading at $82.08, up 0.2%.
More of What's Trending on TheStreet:
- This Part of the U.S. Jobs Market Recovery Has Been One Big Mystery
- This Company Has More Than $450 Billion in Sales and Has a Shot to Take Down Amazon, Jim Cramer Says
- 10 Best-Performing Stocks in the Dow: Cramer's 'Mad Money' Recap
- Tesla Headlines This Lineup of 12 Amazing New Cars for 2018